Literature DB >> 18393632

Control of early fate decisions in human ES cells by distinct states of TGFbeta pathway activity.

Boris Greber1, Hans Lehrach, James Adjaye.   

Abstract

The mechanisms controlling self-renewal versus lineage commitment in human embryonic stem (hES) cells are not well understood. Nonetheless, current knowledge suggests a crucial role for TGFbeta signaling in controlling these early fate decisions. We have investigated the effects of TGFbeta pathway activation and inhibition on gene expression in hES cells. Our data reveal that SMAD 2/3 signaling directly supports NANOG expression, while SMAD 1/5/8 activation moderately represses SOX2. In addition, genes encoding key developmentally relevant signaling molecules and transcription factors appear to be immediately downstream of SMAD 1/5/8 signaling, or require both SMAD 1/5/8 and 2/3 activation, or inactivation of TGFbeta signaling for their induction. Defined stimulation/inhibition of the two TGFbeta branches appeared to control early fate decisions in accordance with these downstream transcriptional effects. Our results therefore help to better understand how pluripotency is mediated at the transcriptional level.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18393632     DOI: 10.1089/scd.2008.0035

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  37 in total

1.  FGF inhibition directs BMP4-mediated differentiation of human embryonic stem cells to syncytiotrophoblast.

Authors:  Smita Sudheer; Raghu Bhushan; Beatrix Fauler; Hans Lehrach; James Adjaye
Journal:  Stem Cells Dev       Date:  2012-08-06       Impact factor: 3.272

Review 2.  A transcriptional roadmap to the induction of pluripotency in somatic cells.

Authors:  Ying Wang; Nancy Mah; Alessandro Prigione; Katharina Wolfrum; Miguel A Andrade-Navarro; James Adjaye
Journal:  Stem Cell Rev Rep       Date:  2010-06       Impact factor: 5.739

Review 3.  Mapping the networks for pluripotency.

Authors:  Kun Xue; Jia-Hui Ng; Huck-Hui Ng
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-08-12       Impact factor: 6.237

4.  Rapid and efficient generation of neurons from human pluripotent stem cells in a multititre plate format.

Authors:  Miao Zhang; Hans R Schöler; Boris Greber
Journal:  J Vis Exp       Date:  2013-03-05       Impact factor: 1.355

5.  Efficient derivation of lateral plate and paraxial mesoderm subtypes from human embryonic stem cells through GSKi-mediated differentiation.

Authors:  Jia Yong Tan; Gopu Sriram; Abdul Jalil Rufaihah; Koon Gee Neoh; Tong Cao
Journal:  Stem Cells Dev       Date:  2013-03-28       Impact factor: 3.272

6.  CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer.

Authors:  Matthew J Meyer; Jodie M Fleming; Amy F Lin; S Amal Hussnain; Erika Ginsburg; Barbara K Vonderhaar
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

Review 7.  Mechanisms of gene regulation in human embryos and pluripotent stem cells.

Authors:  Thorold W Theunissen; Rudolf Jaenisch
Journal:  Development       Date:  2017-12-15       Impact factor: 6.868

8.  SMAD7 directly converts human embryonic stem cells to telencephalic fate by a default mechanism.

Authors:  Mohammad Zeeshan Ozair; Scott Noggle; Aryeh Warmflash; Joanna Ela Krzyspiak; Ali H Brivanlou
Journal:  Stem Cells       Date:  2013-01       Impact factor: 6.277

9.  A data integration approach to mapping OCT4 gene regulatory networks operative in embryonic stem cells and embryonal carcinoma cells.

Authors:  Marc Jung; Hedi Peterson; Lukas Chavez; Pascal Kahlem; Hans Lehrach; Jaak Vilo; James Adjaye
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

10.  The LARGE principle of cellular reprogramming: lost, acquired and retained gene expression in foreskin and amniotic fluid-derived human iPS cells.

Authors:  Katharina Wolfrum; Ying Wang; Alessandro Prigione; Karl Sperling; Hans Lehrach; James Adjaye
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.